Aquestive Therapeutics, Inc. (AQST)
NGM · Healthcare · Drug Manufacturers - Specialty & Generic
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About Aquestive Therapeutics, Inc.
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 10.0M | 12.8M | 13.0M | 14.4M |
| Gross Profit | 5.4M | 8.3M | 7.2M | 11.0M |
| Operating Income | -11.4M | -11.5M | -28.8M | -4.2M |
| Net Income | -13.5M | -15.4M | -31.9M | -8.1M |
| Diluted EPS | $-0.14 | $-0.14 | $-0.26 | $-0.07 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 47.7M | 50.6M | 57.6M | 44.5M |
| Gross Profit | 28.3M | 29.8M | 39.7M | 26.0M |
| Operating Income | -42.1M | -15.1M | -30.8M | -71.1M |
| Net Income | -54.4M | -7.9M | -44.1M | -83.8M |
| Diluted EPS | $-1.12 | $-0.13 | $-0.51 | $nan |